GLP-1 & Incretin Science

An Amylin Analogue Built to Stand Alone

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Petrelintide is a long-acting amylin analogue. Fischer Munch and colleagues published its development in the Journal of Medicinal Chemistry in November 2025 under the description of a potent, stable, long-acting human amylin analogue.

Key facts

Class
Long-acting amylin analogue
Described as
Potent, stable, long-acting, human
Development paper
Fischer Munch 2025 (PMID 41217931)
Journal
J Med Chem, 27 November 2025
Developers
Zealand Pharma with Boehringer Ingelheim
Amylin's role
Satiety signal released after eating
Authorisation
None

What amylin does

The paper's own framing describes amylin as a physiological satiety signal released after nutrient intake, which makes it an attractive pharmacological target for weight management. It is co-secreted with insulin from pancreatic beta cells and signals fullness through routes distinct from the incretins.

Why a separate pathway is worth pursuing

Because it is not the incretin pathway. Every compound engaging GLP-1, GIP or glucagon is working within one hormonal system. Amylin signals satiety through different receptors, so it offers a mechanism that could add to incretin effects rather than overlapping with them, which is the rationale behind pairing them in CagriSema.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why the word human in the title matters

Human amylin aggregates into amyloid fibrils, which is what made the native peptide undeliverable as a medicine and why pramlintide substitutes three residues with prolines borrowed from rat amylin. Describing a compound as a stable human amylin analogue is a claim about having solved that problem within the human sequence rather than by importing rodent residues.

Why long-acting is the other engineering achievement

Native amylin has a very short half-life, and pramlintide requires administration with meals. Extending duration to allow infrequent dosing is a separate problem from preventing aggregation, and solving both in one molecule is what a development paper in a medicinal chemistry journal is reporting.

Why the timing is interesting

REDEFINE 4 showed CagriSema, which pairs an amylin analogue with semaglutide, failing to demonstrate non-inferiority against tirzepatide. That result concerns one combination at one dose pair and says nothing about amylin as a target on its own, which a standalone amylin analogue is positioned to address directly.

Regulatory position

Petrelintide holds no marketing authorisation anywhere and is investigational. Nothing supplied on this site is related to it, and no research material is an amylin analogue or an alternative to any licensed medicine.

Frequently asked questions

Why does 'human' amylin analogue matter?

Human amylin aggregates into amyloid fibrils. Pramlintide avoided that by borrowing rat prolines; a stable human analogue solves it within the human sequence.

Why develop amylin on its own?

REDEFINE 4 tested one amylin-plus-GLP-1 combination, not amylin as a target. A standalone analogue addresses that question directly.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.